Printed From BioPortfolio.com

AZ and Merck & Co get FDA breast cancer nod for Lynparza

06:17 EST 15 Jan 2018 | PMLIVE

It becomes the first PARP inhibitor to be approved outside ovarian cancer

Original Article: AZ and Merck & Co get FDA breast cancer nod for Lynparza

Related Companies
Related Events
Related Clinical Trials
Related PubMed Entries
Related Medications

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topic

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

AZ and Merck & Co get FDA breast cancer nod for Lynparza

More From BioPortfolio on "AZ and Merck & Co get FDA breast cancer nod for Lynparza"

Relevant Topic

News Quicklinks